Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doriano Fabbro

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
Blood|July 21, 2005
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivoElizabeth H Stover, Jing Chen, Benjamin H Lee, et al.
Oncogene|August 24, 2005
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse modelBenjamin H Lee, Ifor R Williams, Ema Anastasiadou, et al.
Journal of Medicinal Chemistry|November 9, 2020
4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological DisordersChiara Borsari, Erhan Keles, Denise Rageot, et al.
British Journal of Pharmacology|November 12, 2019
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: EnzymesStephen P H Alexander, Doriano Fabbro, Eamonn Kelly, et al.
Blood|October 28, 2006
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemiasEllen Weisberg, Laurie Catley, Renee D Wright, et al.
Scientific Reports|September 22, 2018
Acylated-acyl carrier protein stabilizes the Pseudomonas aeruginosa WaaP lipopolysaccharide heptose kinaseNaomi N K Kreamer, Rajiv Chopra, Ruth E Caughlan, et al.
Pharmacology & Therapeutics|August 23, 2002
Protein kinases as targets for anticancer agents: from inhibitors to useful drugsDoriano Fabbro, Stephan Ruetz, Elisabeth Buchdunger, et al.
British Journal of Pharmacology|November 12, 2019
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptorsStephen P H Alexander, Doriano Fabbro, Eamonn Kelly, et al.
Journal of Medicinal Chemistry|June 28, 2019
(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR KinaseDenise Rageot, Thomas Bohnacker, Erhan Keles, et al.
Neuropharmacology|September 5, 2020
Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complexWiebke Theilmann, Birthe Gericke, Alina Schidlitzki, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
Blood|July 21, 2005
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivoElizabeth H Stover, Jing Chen, Benjamin H Lee, et al.
Oncogene|August 24, 2005
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse modelBenjamin H Lee, Ifor R Williams, Ema Anastasiadou, et al.
Journal of Medicinal Chemistry|November 9, 2020
4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological DisordersChiara Borsari, Erhan Keles, Denise Rageot, et al.
British Journal of Pharmacology|November 12, 2019
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: EnzymesStephen P H Alexander, Doriano Fabbro, Eamonn Kelly, et al.
Blood|October 28, 2006
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemiasEllen Weisberg, Laurie Catley, Renee D Wright, et al.
Scientific Reports|September 22, 2018
Acylated-acyl carrier protein stabilizes the Pseudomonas aeruginosa WaaP lipopolysaccharide heptose kinaseNaomi N K Kreamer, Rajiv Chopra, Ruth E Caughlan, et al.
Pharmacology & Therapeutics|August 23, 2002
Protein kinases as targets for anticancer agents: from inhibitors to useful drugsDoriano Fabbro, Stephan Ruetz, Elisabeth Buchdunger, et al.
British Journal of Pharmacology|November 12, 2019
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptorsStephen P H Alexander, Doriano Fabbro, Eamonn Kelly, et al.
Journal of Medicinal Chemistry|June 28, 2019
(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR KinaseDenise Rageot, Thomas Bohnacker, Erhan Keles, et al.
Neuropharmacology|September 5, 2020
Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complexWiebke Theilmann, Birthe Gericke, Alina Schidlitzki, et al.
Pageof 13